Co-Founder & CEO Peter Fedichev describes why he believes reading the amino acid sequences that have been written into the human genome over time is a more realistic way of discovering small molecules that will work rather than via protein-target structure models. He also discovers how the company is leveraging this for its focus on aging conditions and longevity.
View all episodes
By BiotechTV
4.3
66 ratings
Co-Founder & CEO Peter Fedichev describes why he believes reading the amino acid sequences that have been written into the human genome over time is a more realistic way of discovering small molecules that will work rather than via protein-target structure models. He also discovers how the company is leveraging this for its focus on aging conditions and longevity.
3,222 Listeners
1,910 Listeners
124 Listeners
324 Listeners
61 Listeners
9,957 Listeners
86 Listeners
34 Listeners
353 Listeners
19 Listeners
60 Listeners
512 Listeners
41 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners
48 Listeners